Why the study?
Does prostaglandin E2 improve random skin flap survival in a porcine model?
Does prostaglandin E2 improve random skin flap survival in a porcine model?
Prostaglandin E2 infusion significantly improves random skin flap survival in a porcine model, which strongly correlates with increased red blood cell flexibility.
May enhance random skin flap survival in porcine models; hypothesis-generating and requires human trials before clinical adoption.
This study evaluated the effect of prostaglandin E2 on skin flap survival in the porcine model. Dorsal random skin flaps on hypopigmented 15- to 25-kg pigs were used. Prostaglandin E2 (10 ng/kg per minute) was infused for 2 days prior to surgery and continued during the 7-day postoperative period. Mean flap survival was 52.58% +/- 3.62% for the control group and 68.51% +/- 3.34% for the experimental group (P < .05). A moderate correlation existed between prostaglandin E2 serum levels and flap viability. A strong correlation was noted between red blood cell flexibility and the amount of flap survival (r = .86). As red blood cell flexibility increased, the survival percentage also increased. Although prostaglandin E2 reduced adenosine diphosphate-induced platelet aggregation from a baseline of 86.08% +/- 8.33% to 54.61% +/- 17.21%, no correlation was noted between the amount of platelet aggregation and percent flap survival (r = .52).
No takes yet. Share an insight, caveat, or question.
Layton et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: